CVRx Inc
CVRX
Company Profile
Business description
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Contact
9201 West Broadway Avenue
Suite 650
MinneapolisMN55445
USAT: +1 763 416-2840
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
223
Stocks News & Analysis
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks
Wide moat healthcare leader remains undervalued
ASX healthcare giant expected to see uptick in demand from emerging markets.
stocks
This US AI winner has been unstoppable. Is it time to sell?
Astonishing results have driven this AI stock into significantly overvalued territory.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,858.80 | 76.70 | -0.86% |
| CAC 40 | 8,244.29 | 0.00 | 0.00% |
| DAX 40 | 24,944.95 | 149.01 | 0.60% |
| Dow JONES (US) | 51,561.93 | 874.86 | 1.73% |
| FTSE 100 | 10,360.32 | 28.02 | 0.27% |
| HKSE | 25,014.66 | 238.74 | -0.95% |
| NASDAQ | 26,830.96 | 23.02 | -0.09% |
| Nikkei 225 | 66,791.52 | 679.16 | -1.01% |
| NZX 50 Index | 13,161.97 | 60.36 | 0.46% |
| S&P 500 | 7,584.31 | 30.63 | 0.41% |
| S&P/ASX 200 | 8,629.60 | 75.50 | -0.87% |
| SSE Composite Index | 4,059.00 | 1.22 | 0.03% |